Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis
This study has been completed.
Information provided by (Responsible Party):
Raptor Pharmaceuticals Inc.
First received: March 27, 2009
Last updated: June 10, 2015
Last verified: June 2015
Cystinosis is an inheritable disease that if untreated, results in kidney failure as early as the first decade of life. The current marketed therapy is Cystagon® (cysteamine bitartrate) which must be taken every six hours for the rest of the patient's life to prevent complications of cystinosis. RP103 is a formulation of cysteamine bitartrate that is being studied to see if it may be able to be given less frequently, once every 12 hours, and have similar results.
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Pilot Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cysteamine Bitartrate (Cystagon®) in Patients With Nephropathic Cystinosis
Primary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||October 2009 (Final data collection date for primary outcome measure)
Active Comparator: Cystagon®
Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg
Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.
Duration of Treatment and Dose: Reference Period up to four doses Q6H.
Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg
Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.
Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product.
This is a single-dose, open-labeled, non-randomized, two-period study of Cysteamine Bitartrate Delayed-release Capsules (RP103) and Cystagon® in up to 10 patients (male or female) with nephropathic cystinosis under fasting conditions. It will involve a 4 night check-in to a clinical research center.
|Ages Eligible for Study:
||Child, Adult, Senior
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Male and female subjects must have nephropathic cystinosis.
- Children less than 22.5 kg will only be included in the study if the investigator feels they can safely participate in the study including the required blood draw volume for the safety and PK/PD assessments.
- Subjects must be on a stable dose of Cystagon® at least 21 days prior to Screening.
- Subjects must be able to swallow a 150 mg Cystagon® capsule with the capsule intact.
- Within the last 2 months, no clinically significant change in liver function [i.e., ALT, AST, alkaline phosphatase, bilirubin (total and direct)] and renal function [i.e., serum creatinine, albumin, total protein] at Screening as determined by the Investigator.
- Sexually active female subjects of childbearing potential (i.e., not surgically sterile [tubal ligation, hysterectomy, or bilateral oophorectomy] or at least 2 years naturally postmenopausal) must agree to utilize the same acceptable form of contraception from screening through completion of the study.
- Subjects or their authorized caregiver must provide written informed consent and assent (where applicable) prior to participation in the study.
- If in the opinion of the investigator, patients can safely provide the study required blood draw volume.
- Subjects must be willing and able to comply with the study restrictions and requirements.
- If, in the opinion of the investigator, the planned study dose would exceed the patient's tolerability of cysteamine based on their prior Cystagon® steady state drug requirements.
- Evidence of or verbal attestation of Helicobacter pylori infection, presently, or within the last 90 days prior to Screening.
- Subjects with a known history, currently or within the past 90 days prior to Screening, of the following conditions or other health issues that make it, in the opinion of the investigator, unsafe for them to participate, or whose concomitant medical problems preclude them from committing to the study schedule including the following: Crohn's disease, inflammatory bowel disease (if currently active) or have had prior resection of small intestine; • History of heart disease, e.g., myocardial infarction, heart failure, arrhythmias; Any bleeding disorder; Malignant disease; Severe liver disease as defined as ALT or AST > 2 times the upper limit of normal.
- Subjects who have had a kidney transplant.
- Subjects who are planning or are a registered candidate for a kidney transplant within 3 months of the Screening or have a serum creatinine > 2.4.
- Subjects with known hypersensitivity to cysteamine.
- If female (of child-bearing potential), are nursing, planning a pregnancy, known or suspected to be pregnant, or have a positive urine pregnancy screen.
- Patients with a hemoglobin level < 10.5.
- Subjects who have a made a blood donation within 60 days prior to study initiation.
- Subjects who, in the opinion of the Investigator, are not able or willing to comply with the protocol.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00872729
|University of California San Diego Medical Center
|San Diego, California, United States, 92103 |
Raptor Pharmaceuticals Inc.
||Bruce Barshop, MD, PhD
||Raptor Pharmaceuticals Inc.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 27, 2009
|Results First Received:
||October 5, 2012
||June 10, 2015
||United States: Food and Drug Administration
Keywords provided by Raptor Pharmaceuticals Inc.:
CTNS protein, human
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 25, 2016
Lysosomal Storage Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Renal Tubular Transport, Inborn Errors
Cystine Depleting Agents
Molecular Mechanisms of Pharmacological Action